A Practical Guide to Pan Coating and Scale-Up - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Practical Guide to Pan Coating and Scale-Up
An understanding of the pan-coating process based on first principles can support successful scale up.


Equipment and Processing Report


Scaling up the coating process
Various articles on scale-up principles have been published (1–3). The following basic scale-up principles can be applied easily in practice.

Pan size. Batch size scale-up is largely dependent on the pan size. As a general rule, the bed depth in proportion to the pan depth should be kept constant. This proportion will help to achieve consistent tablet flow in the scale-up batch, assuming the pans have similar dimensions. However, the technique can also be useful even if the pans are not geometrically similar.

Pan RPM. RPM scale-up is based on the industry’s accepted principle of using the linear distance travelled by tablets in the pan per unit time as constant and can be applied to obtain similar dynamic conditions during scale-up. The linear distance is calculated as πD, where D is the pan diameter.

Pan RPM can be calculated using Equation 4.



Air flow scale-up. Air flow is frequently limited by the particular equipment and/or blowers installed on the system. It is important—particularly for functional coatings—to keep the drying kinetics constant as the process is scaled up. This action can be accomplished in accordance with the spray rate scale-up presented below.

Spray rate. Spray rate scale-up needs to be in step with air flow scale-up. The coordination should be based on more than the batch size increase because equipment that provides a five-fold batch size increase may only allow a two-fold increase in process air. As a general rule, product temperature should be constant across scales. It is often possible to increase the temperature to allow for higher spray rate during scale-up, but this increase depends on the sensitivity of the coating material, or polymer, and its film-forming properties.

The general principles described above underpin the tablet coating process and can support successful scale-up.

References

1. R. Turton and X.X. Cheng, Powder Tech., 150, 78–85 (2005).
2. S.C. Porter, "Scale-up of Film Coating," Pharmaceutical Process Scale-Up, M. Levin, Ed., (Marcel Dekker Inc, New York, USA, 2000), pp. 259–310.
3. G.B. Tatterson, Scaleup and Design of Industrial Mixing Processes (McGraw Hill, New York, 1994).

Abhishek Kathuria is manager of formulations at J&J Consumer Healthcare, Fort Washington, PA.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Equipment and Processing Report,
Click here